Claudia Fischbach-Teschl, Ph.D., is the Stanley Bryer 1946 Professor of Biomedical Engineering the Nancy E. and Peter C. Meinig School of Biomedical Engineering at Cornell University. She received her Ph.D. in Pharmaceutical Technology from the University of Regensburg, Germany, and holds an M.S. in Pharmacy from the Ludwigs-Maximilians-University, Munich, Germany. She conducted her postdoctoral work at Harvard University in the Division of Engineering and Applied Sciences and joined the faculty of Cornell in 2007. Her research utilizes engineering tools and strategies to gain a better understanding of cancer development, progression, and therapy resistance with a particular focus on adipose stroma contributions to breast cancer, bone metastasis and tumor angiogenesis. She is a fellow of the American Institute for Medical and Biological Engineering, the Biomedical Engineering Society, and the Humboldt Foundation in Germany.  Project 1 Leader

Lewis C. Cantley, Ph.D., is Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College and New York Presbyterian Hospital.  Dr. Cantley obtained a Ph.D. in biophysical chemistry from Cornell University in 1975 and did postdoctoral training at Harvard University.  Prior to taking the position at Weill Cornell, he taught and did research in biochemistry, physiology and cancer biology in Boston at Harvard, at Tufts University School of Medicine and most recently at Beth Israel Deaconess Medical Center and Harvard Medical School.  His laboratory discovered the PI 3-Kinase pathway that plays a critical role in insulin signaling and in cancers.